Home » Stocks » ITCI

Intra-Cellular Therapies Inc. (ITCI)

Stock Price: $41.68 USD -1.65 (-3.81%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 3.38B
Revenue (ttm) 37.61M
Net Income (ttm) -232.34M
Shares Out 80.95M
EPS (ttm) -3.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $41.68
Previous Close $43.33
Change ($) -1.65
Change (%) -3.81%
Day's Open 43.59
Day's Range 41.28 - 43.94
Day's Volume 695,063
52-Week Range 17.26 - 43.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg

5 days ago - GlobeNewsWire

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 10.96% over the past year to ($0.65), which beat the esti...

1 month ago - Benzinga

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review ...

1 month ago - GlobeNewsWire

NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...

1 month ago - GlobeNewsWire

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT

1 month ago - GlobeNewsWire

Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director Board of ...

1 month ago - GlobeNewsWire

Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory co...

2 months ago - GlobeNewsWire

Searching for drug developers that are innovative, but come with relatively low risk? Look no further.

Other stocks mentioned: BNTX, EXEL
2 months ago - The Motley Fool

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 10.59% and 0.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.

3 months ago - GlobeNewsWire

Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in collabora...

3 months ago - Benzinga

ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particula...

3 months ago - GlobeNewsWire

Intra-Cellular Therapies Inc (NASDAQ: ITCI) submits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults. ...

3 months ago - Benzinga

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

3 months ago - GlobeNewsWire

Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to previo...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...

5 months ago - GlobeNewsWire

The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.

5 months ago - GlobeNewsWire

After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And it's been trading in cyclical growth spurts of gives and takes. Investors...

6 months ago - Seeking Alpha

These two biotech companies are safe bargains in today's volatile market.

Other stocks mentioned: ALXN
6 months ago - The Motley Fool

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...

6 months ago - GlobeNewsWire

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 17.71% and 12.97%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) remained unaffected after the company reported Q3 results.

7 months ago - Benzinga

P ositive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.

7 months ago - GlobeNewsWire

Innovation might be worth the high risk up front investment.

Other stocks mentioned: CRSP
7 months ago - The Motley Fool

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nerv...

7 months ago - GlobeNewsWire

These companies show that specialization can be an excellent competitive strategy.

Other stocks mentioned: VRTX
8 months ago - The Motley Fool

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...

8 months ago - GlobeNewsWire

The potential label expansion of lumateperone in bipolar depression could be a major breakthrough.

8 months ago - The Motley Fool

NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

8 months ago - GlobeNewsWire

Shares of a New York City biotechnology company shot up nearly 73% Wednesday, sparked by news that a drug it's testing could hit sales of more than $1 billion, earning it blockbuster status.

9 months ago - GuruFocus

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public off...

9 months ago - GlobeNewsWire

A nice bounce for the market was overdue.

Other stocks mentioned: LULU
9 months ago - The Motley Fool

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $350 mi...

9 months ago - GlobeNewsWire

Intra-Cellular Therapies (ITCI) is in the news Wednesday after announcing positive results from a recent study that sent ITCU stock soaring. The post Intra-Cellular Therapies News: Why ITCI Stock Is Sky...

9 months ago - InvestorPlace

Intra-Cellular Therapies on Wednesday revealed positive final-phase test results for a treatment for certain Bipolar I and Bipolar II disorders, sending ITCI stock soaring more than 70%. The post Positi...

9 months ago - Investors Business Daily

Investors are reacting enthusiastically to the company's latest clinical results.

9 months ago - The Motley Fool

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipolar disorder.

9 months ago - 24/7 Wall Street

Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and...

9 months ago - GlobeNewsWire

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.

10 months ago - Benzinga

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

10 months ago - GlobeNewsWire

NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central ne...

10 months ago - GlobeNewsWire

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing...

11 months ago - GlobeNewsWire

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, t... [Read more...]

Industry
Biotechnology
CEO
Sharon Mates
Employees
383
Stock Exchange
NASDAQ
Ticker Symbol
ITCI
Full Company Profile

Financial Performance

In 2020, ITCI's revenue was $22.81 million, an increase of 37,537.11% compared to the previous year's $60,613. Losses were -$227.01 million, 53.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is 52.13, which is an increase of 25.07% from the latest price.

Price Target
$52.13
(25.07% upside)
Analyst Consensus: Strong Buy